Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 271 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Synchronized Swimmer Learns She Has Breast Cancer After Teammate Kicks Her... March 4, 2020 Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... February 12, 2024 EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment... May 17, 2024 Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... February 5, 2026 Load more HOT NEWS ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March Cincinnati Police Are Wearing Pink Badges For Breast Cancer Awareness ESMO Welcomes Launch of Health Package Introducing EU Measures That Can...
